Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-03-26 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2017年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2017 年度内部控制自我评价报告' which translates to '2017 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control evaluation for the year ending December 31, 2017, including the scope, standards, and conclusions about internal control effectiveness. The content focuses on internal control assessment rather than full financial statements or audit opinions. It is not an Annual Report (10-K) or Audit Report (AR) but a specialized internal control evaluation report. Given the nature of the document as an internal control self-evaluation report, it fits best under Audit Report / Information (AR), which includes applied accounting principles and internal control results but excludes full annual reports. The document length is under 5,000 characters, but it contains substantive content, not just an announcement. Therefore, the classification is AR with high confidence. FY 2017
2018-03-26 Chinese
2017年度独立董事述职报告（韩文君）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2017, issued by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision of internal controls, and other governance-related activities during the year. The content focuses on the director's duties and oversight rather than presenting financial statements or audit results. It is not an annual report, audit report, or earnings release. It is also not a regulatory filing or announcement. The document is a detailed report by a board member on their management and governance activities, which fits the category of Board/Management Information (MANG). The document length is about 3,031 characters, which is consistent with a detailed management or board report rather than a brief announcement or a full financial report.
2018-03-26 Chinese
关于增加理财产品购买额度的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the increase in the purchase limit for low-risk, short-term bank financial products using the company's own idle funds. It details the board resolutions, investment purpose, amount, risk analysis, and approvals by independent directors and the supervisory board. The document is a disclosure of a corporate financing activity related to the use of idle funds for investment in financial products, not a financial report, earnings release, or management discussion. It is not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and capital usage.
2018-03-26 Chinese
关于会计政策变更的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding a change in accounting policies. It details the reasons for the change, references specific accounting standards issued by the Ministry of Finance, explains the impact on financial statement presentation, and includes approvals from the board and supervisory committee. The document is relatively short (2303 characters) and does not contain actual financial statements or detailed financial data. It is a formal announcement about a change in accounting policy rather than a full audit report or annual/interim report. It does not fit the criteria for Annual Report (10-K), Audit Report (AR), or Interim Report (IR). It is not a certification letter or a regulatory compliance filing. The content is focused on management and board decisions about accounting policy changes, which aligns best with Board/Management Information (MANG).
2018-03-26 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) for the year ending December 31, 2017, issued by an accounting firm (瑞华会计师事务所). It contains detailed evaluation and assurance on the effectiveness of internal controls related to financial reporting, including standards, scope, and conclusions. The document is not a full annual report (10-K), nor is it a simple announcement or certification. It is a standalone audit-related assurance report focusing on internal control effectiveness, which fits the definition of an Audit Report / Information (AR). The document length (4559 characters) is sufficient to contain substantive content, not just an announcement. Therefore, the classification is AR with high confidence. FY 2017
2018-03-26 Chinese
2017年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' (Audit Report) and is issued by 瑞华会计师事务所 (Ruihua Certified Public Accountants) with a specific audit report number for the year 2017. It contains detailed audit opinions, basis for audit opinions, key audit matters, responsibilities of management and auditors, and includes full financial statements such as consolidated balance sheets, income statements, cash flow statements, and equity changes for the fiscal year ending December 31, 2017. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content is consistent with a standalone audit report rather than a full annual report or other filing types. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2017
2018-03-26 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.